You linked a mention of CytoDyn at the Asia Bio Partnering Forum 2026 on Sept. 1 – 2 in Singapore. Here is a summary from their website:
Cytodyn Inc.
CytoDyn is a clinical-stage biotechnology company advancing leronlimab, a CCR5-targeting monoclonal antibody with potential across multiple solid tumor indications. By blocking CCR5, a key regulator of immune cell trafficking and tumor progression, leronlimab is designed to modulate the tumor microenvironment and enhance anti-tumor immune responses, reducing metastatic potential.
CytoDyn is pursuing a flexible development strategy that includes both monotherapy and its "prime and pair" approach, where leronlimab is used to improve responsiveness to standard-of-care and immuno-oncology combinations. This strategy is supported by translational and clinical data, including initial circulating tumor DNA readouts presented at AACR, with additional updates expected through 2026.
CytoDyn's lead program focuses on metastatic colorectal cancer, where the Phase 2 CLOVER study is evaluating leronlimab with TAS-102 and bevacizumab in heavily pretreated MSS patients. The study has completed enrollment and is showing early promising clinical and biomarker signals.
CytoDyn recently announced a strategic collaboration to evaluate circulating tumor DNA (ctDNA) dynamics and generate real-world molecular insights to support CytoDyn's metastatic colorectal cancer development program.
Company Presentations Biotech (Jasmine Ballroom 3803)
Tuesday, 1 September 2026 11:00 - 11:15
I just saw that BuildGoodThings posted about this conference in reddit. CFO Hoffman was the presenter.
https://www.reddit.com/r/Livimmune/comments/1...1_at_11pm/